- PMLiVE

Neurodiversity and healthcare communications – do we know enough and do we do enough?

By Robert Goodwin

- PMLiVE

World Antimicrobial Awareness Week 2022

Reports from the World Health Organization show that AMR is one of the top ten threats to global health, causing 1.3 million deaths in 2019

- PMLiVE

Design considerations and best practices in clinical research

The increased focus on precision medicine in oncology and rare diseases has led to a marked increase of single-arm trials

- PMLiVE

Unlocking the potential of data sharing

The impact of privacy issues on clinical trials – how these issues limit studies and how they can be optimised

- PMLiVE

FDA approves Ferring’s Adstiladrin as first gene therapy for bladder cancer

Non-muscle-invasive bladder cancer represents around 75% of all new bladder cancer cases

- PMLiVE

ICR twin study indicates childhood leukaemia begins in the womb

The study, published in Leukemia, will help clinicians advise parents of twins with ALL

- PMLiVE

Mind the gender gap: how marcomms can tackle gender health inequality

By Kesha Tansey and Emma Moss

- PMLiVE

The challenges of the proposed Data Protection and Digital Information Bill

Why the new Bill may cause more complexity and confusion for businesses operating outside the UK

- PMLiVE

How and when should we innovate our strategies to deliver competitive change?

Understanding the five mistakes to avoid in order to ensure brand success

- PMLiVE

The role of medical communications in building credibility for healthtech

By Sarah Funderburk

- PMLiVE

Focusing on ‘treating the patient, not the disease’ can transform the outlook for cardiovascular disease

Sharpening the focus to ‘treating the patient, not the disease’ can lead to a paradigm shift in outcomes

- PMLiVE

Retrospective prospective

Looking back at what we learned in 2022 and what the new year may bring

- PMLiVE

Assessing the impact of rarity on French HTA and pricing decisions

With changes to the pricing and access processes such as the new Accord Cadre and the soon-to-be implemented ATU reform likely to impact pricing and access of orphan products in...

- PMLiVE

Creative destruction

Biotech’s problems create opportunities for others

- PMLiVE

Addressing the diversity issue in clinical trials

How patient-centric analytics can be used to design more diverse, inclusive and equitable trials